Literature DB >> 31005338

Clinical practice patterns in laryngeal cancer and introduction of CT lung screening.

Krzysztof Piersiala1, Lee M Akst2, Alexander T Hillel2, Simon R Best3.   

Abstract

OBJECTIVES: After the publication of large clinical trials, in January 2014 The U.S. Preventive Services Task Force (USPSTF) recommended annual lung cancer screening with low-dose CT in a well-defined group of high-risk smokers. A significant proportion of patients with laryngeal cancer (LC) meet the introduced criteria, and we hypothesized that clinical practice would change as a result of these evidence-based guidelines.
METHODS: Retrospective chart review of patients diagnosed with LC and treated at Johns Hopkins Hospital who met USPSTF criteria for annual chest screening and were followed for at least 3 consecutive years in the years surrounding the introduction of screening guidelines (January 2010 to December 2017) was performed to identify those who had recommended screening CT chest.
RESULTS: A total of 151 patients met the inclusion criteria of the study and were followed for a total of 746 patient-years. 184/332 (55%) patient-years in the pre-guidelines period and 246/414 (59%) in the post-guidelines period included at least one recommended chest imaging (CT or PET-CT; p = 0.27). 248/332 (75%) patient-years in the pre-guidelines period and 314/414 (76%) in the post-guidelines period included any radiological chest imaging (X-ray, CT or PET-CT; p = 0.72). Screening scans were ordered by OHNS (45%), Medical Oncology (31%), Radiation Oncology (8%), and primary care (14%) with 70% of patients missing at least one year of indicated screening.
CONCLUSIONS: The implementation of new lung cancer screening guidelines did not change clinical practice in the management of patients with LC and many patients do not receive recommended screening. Further study concerning potential barriers to effective evidence-based screening and coordination of care is warranted.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT; Head and neck cancer; Laryngeal cancer; Lung cancer; Lung cancer screening

Mesh:

Year:  2019        PMID: 31005338      PMCID: PMC6570546          DOI: 10.1016/j.amjoto.2019.04.010

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  17 in total

1.  Annual smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 1997-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-07-01       Impact factor: 17.586

2.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

3.  Second malignant neoplasia in early (TIS-T1) glottic carcinoma.

Authors:  Elisabeth V Sjögren; Simone Snijder; Joost van Beekum; Robert Jan Baatenburg de Jong
Journal:  Head Neck       Date:  2006-06       Impact factor: 3.147

4.  Risk factors for the development of second primary tumors among men after laryngeal and hypopharyngeal carcinoma.

Authors:  Rajesh P Dikshit; Paolo Boffetta; Christine Bouchardy; Franco Merletti; Paolo Crosignani; Teresa Cuchi; Eva Ardanaz; Paul Brennan
Journal:  Cancer       Date:  2005-06-01       Impact factor: 6.860

5.  Second primary malignancies in squamous cell carcinomas of the tongue and larynx: an analysis of incidence, pattern, and outcome.

Authors:  Yen-Bin Hsu; Shyue-Yih Chang; Ming-Chin Lan; Jui-Lin Huang; Shyh-Kuan Tai; Pen-Yuan Chu
Journal:  J Chin Med Assoc       Date:  2008-02       Impact factor: 2.743

6.  Laryngeal cancer: epidemiological data from Νorthern Greece and review of the literature.

Authors:  K Markou; A Christoforidou; I Karasmanis; G Tsiropoulos; S Triaridis; I Constantinidis; V Vital; A Nikolaou
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

7.  Detection of human papillomavirus and adenovirus in benign and malignant lesions of the larynx.

Authors:  Andrea Gallo; Anna Marta Degener; Giulio Pagliuca; Alessandra Pierangeli; Federica Bizzoni; Antonio Greco; Marco de Vincentiis
Journal:  Otolaryngol Head Neck Surg       Date:  2009-08       Impact factor: 3.497

8.  Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.

Authors:  Annah Wyss; Mia Hashibe; Shu-Chun Chuang; Yuan-Chin Amy Lee; Zuo-Feng Zhang; Guo-Pei Yu; Deborah M Winn; Qingyi Wei; Renato Talamini; Neonila Szeszenia-Dabrowska; Erich M Sturgis; Elaine Smith; Oxana Shangina; Stephen M Schwartz; Stimson Schantz; Peter Rudnai; Mark P Purdue; Jose Eluf-Neto; Joshua Muscat; Hal Morgenstern; Pedro Michaluart; Ana Menezes; Elena Matos; Ioan Nicolae Mates; Jolanta Lissowska; Fabio Levi; Philip Lazarus; Carlo La Vecchia; Sergio Koifman; Rolando Herrero; Richard B Hayes; Silvia Franceschi; Victor Wünsch-Filho; Leticia Fernandez; Eleonora Fabianova; Alexander W Daudt; Luigino Dal Maso; Maria Paula Curado; Chu Chen; Xavier Castellsague; Marcos Brasilino de Carvalho; Gabriella Cadoni; Stefania Boccia; Paul Brennan; Paolo Boffetta; Andrew F Olshan
Journal:  Am J Epidemiol       Date:  2013-06-30       Impact factor: 4.897

9.  Human papillomavirus in early laryngeal carcinoma.

Authors:  Jessica L Baumann; Seth Cohen; Amy N Evjen; Jonathan H Law; Sangeetha Vadivelu; Albert Attia; Joshua S Schindler; Christine H Chung; Pamela S Wirth; Chris J L M Meijer; Peter J F Snijders; Wendell G Yarbrough; Robbert J C Slebos
Journal:  Laryngoscope       Date:  2009-08       Impact factor: 3.325

10.  Diagnosis of second head and neck tumors in primary laryngeal SCC is an indicator of overall survival and not associated with poorer overall survival: a single centre study in 987 patients.

Authors:  Ross Darius Farhadieh; Arash Salardini; Jia Lin Yang; Pamela Russell; Robert Smee
Journal:  J Surg Oncol       Date:  2010-01-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.